U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489716) titled 'A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer' on March 18.
Brief Summary: This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Interven...